The protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity;Sisplatin ototoksisitesinde dekzametazon ve laktat'ın koruyucu etkinliǧi

Turkish Journal of Medical Sciences

Volumn 41, Issue 3, 2011, Pages 467-474

  Şanli, Arif ^a   Aydin, Sedat ^a   Sarisoy, Zeynep Alev ^b   Paksoy, Mustafa ^a   Ayduran, Emin ^c   Erdivanli, Özlem Çelebi ^d  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Giresun Governmet Hospital   (Turkey)

^c irnak Military Hospital   (Turkey)

^d Rize Devlet Hastanesi   (Turkey)

Author keywords

Cisplatin; Dexamethasone; Intratympanic route; Lactated ringer's solution; Otoprotection; Ototoxicity; Rat

Indexed keywords

DEXAMETHASONE; LACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY THRESHOLD SHIFT; CONTROLLED STUDY; EAR PROTECTION; EVOKED BRAIN STEM AUDITORY RESPONSE; HEARING LOSS; HEARING TEST; NONHUMAN; OTOTOXICITY; RAT; WISTAR RAT;

EID: 79955563124     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1005-850     Document Type: Article

References (30)

1. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005; 10: 1313-21.
2. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355-62.
3. Ayan N, Ayan İ, Aydin S, Kebudi R, Gürsel AO, Bilge N. Cisplatin tedavisi alan çocuklarda ototoksisite. Beyoǧlu 1991; 1: 43-9.
4. Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 2006; 70: 177-84.
5. Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990; 100: 724-34.
6. Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120: 541-6.
7. Clerici WJ, DiMartino DL, Prasad MR. Direct Effect s of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear Res 1995; 84: 30-40.
8. Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 2001; 174: 27-34.
9. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000; 21: 513-20.
10. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin induced ototoxicity and prevention. Hear Res 2007; 226: 157-67.
11. Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB, Mason J et al. Intratympanic steroid treatment: a review. Otol Neurotol 2004; 25: 1034-9.
12. Kolls J, Xie J, LeBlanc R, Malinski T, Nelson S, Summer W et al. Rapid induction of messenger RNA for nitric oxide synthase II in rat neutrophils in vivo by endotoxin and its suppression by prednisolone. Proc Soc Exp Biol Med 1994; 205: 220-9.
13. Nagura M, Iwasaki S, Wu R, Mizuta K, Umemura K, Hoshino T. Effect s of corticosteroid, contrast medium and ATP on focal microcirculatory disorders of the cochlea. Eur J Pharmacol 1999; 366: 47-53.
14. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol 2006; 27: 564-9.
15. Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004; 25: 910-5.
16. Hannemann J, Baumann K. Inhibition of lactatedehydrogenase by cisplatin and other platinum-compounds: enzyme leakage of LDH is not a suitable method to measure platinum-compound-induced kidney cell damage in vitro. Res Commun Chem Pathol Pharmacol 1988; 60: 371-9.
17. Van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006; 32: 390-7.
18. Cardinaal RM, De Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? Hear Res 2000; 144: 147-56.
19. Van Ruijven MW, De Groot JC, Klis SF, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005; 205: 241-8.
20. Watanabe KI, Hess A, Bloch W, Michel O. Nitric oxide synthase inhibitor suppresses the ototoxic side Effect of cisplatin in guinea pigs. Anticancer Drugs 2000; 11: 401-6.
21. Li G, Frenz DA, Brahmblatt S, Feghali JG, Ruben RJ, Berggren D et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 2001; 22: 163-76.
22. Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben RJ, Rybak L, Van de Water TR. Use of organotypic cultures of Corti's organ to study the protective Effect s of antioxidant molecules on cisplatininduced damage of auditory hair cells. Am J Otol 1997; 18: 559-71.
23. Kaltenbach JA, Church MW, Blakley BW, McCaslin DL, Burgio DL. Comparison of fi ve agents in protecting the cochlea against the ototoxic Effect s of cisplatin in the hamster. Otolaryngol Head Neck Surg 1997; 117: 493-500.
24. Kamimura T, Whitworth CA, Rybak LP. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hear Res 1999; 131: 117-27.
25. Korver KD, Rybak LP, Whitworth C, Campbell KM. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 2002; 126: 683-9.
26. Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative Effect s of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res 1995; 86: 195-203.
27. Reser D, Rho M, Dewan D, Herbst L, Li G, Stupak H et al. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology 1999; 20: 731-48.
28. Daldal A, Odabasi O, Serbetcioglu B. The protective Effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007; 137: 747-52.
29. Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: Effect of intratympanic dexamethasone injections. Otol Neurotol 2008; 29: 1005-11.
30. Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007; 28: 1124-30.